^
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive
:
A1
Merck (MSD) Press Release - 3d
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive
:
A1
Merck (MSD) Press Release - 3d
HER-2 positive
Gastric Cancer
RC48
Sensitive
:
C3
Gastric Cancer - 4d
HER-2 overexpression + PTEN deletion
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Resistant
:
C3
Sci Rep - 1wk
dMMR/MSI-H + TMB-L
Gastric Cancer
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Gastric Cancer
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
HER-2 1899‐1G>A
Gastric Adenocarcinoma
trastuzumab
Resistant
:
C4
The Oncologist - 1wk
FGFR2b overexpression + HER2 negative
Gastric Cancer
FPA-144
Sensitive
:
B
Amgen Press Release - 2wk
FGFR2b overexpression + HER2 negative
Gastroesophageal Junction Adenocarcinoma
FPA-144
Sensitive
:
B
Amgen Press Release - 2wk
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
FDA - 3wk
No biomarker
Gastric Cancer
nivolumab
Sensitive
:
A1
FDA - 3wk
MET amplification
Gastric Adenocarcinoma
crizotinib
Sensitive
:
C3
Target Oncol - 3wk
MET amplification
GastroEsophageal Cancer
crizotinib
Sensitive
:
C3
Target Oncol - 3wk
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
No biomarker
Gastric Cancer
TPF
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive
:
A1
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Gastric Cancer
pembrolizumab
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Trazimera (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
Trazimera (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
Ogivri (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Herzuma (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
Herzuma (trastuzumab biosimilar)
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine/tipiracil
Sensitive
:
A1
No biomarker
Gastric Cancer
trifluridine/tipiracil
Sensitive
:
A1
No biomarker
Gastric Cancer
ramucirumab
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our